Reviewed 2026-05-16 | Source thesis: output/graham/scores/RI_PA_thesis.md (Feb 2026, T1 executed at EUR 73.24)
Transcripts fetched via the klip-politik yt-dlp + WARP recipe (see reference_klip_politik_yt_tools.md in auto-memory). Working files in /home/pengacau/pasar-malam/.tmp-yt/ (cleaned .txt per video id).
| # | Video ID | Channel | Length | Position | Quality |
|---|---|---|---|---|---|
| 1 | 3RUDzNNxFbM |
Sven Carlin — Diageo & Pernod Ricard Stock Analysis | 4:36 EN | Bearish (pass) | Low — thematic, self-promo, no PR-specific analysis |
| 2 | BXhmc1YQf_I |
The German Value Investor — Everyone Is Buying… But Should You? | 8:34 EN | Bearish (pass) | High — substantive financials, EV-based critique |
| 3 | Fj0bcqXbYJE |
Moritz Hessel — Pernod Ricard? Ich kaufe! [Gigant im Tief!] | 26:27 DE | Bullish, holds, sees +100% | High — best EM/structural analysis of the four |
| 4 | hQbiXjtnarQ |
Neffets/Steffen — 70% CRASH – Historische Chance oder Falle? | 14:00 DE | Cautious watchlist (not yet buying) | Solid technical/fundamental, weak on EM |
Videos 2 and 4 reference current price ~EUR 63 (recent). Video 3 references EUR 75 and Q1 FY26 China -21% / US -6% → filmed earlier (~Feb–Mar 2026). Video 4 treats BF.B merger as live → pre-Apr 28 termination.
| Thesis claim | Confirming videos | Notes |
|---|---|---|
| ~63–70% drawdown from EUR 218 peak | 2, 4 | Both cite EUR 217/214 peak |
| H1 FY26 organic weakness (US -15%, China -28%) | 2, 4 | Exact numbers match thesis ^13 |
| Gross margin ~60% holding | 2, 4 | Above our trim-at-55% threshold |
| Family-led, long-term orientation, EM-first | 3 | Hessel makes this his core thesis — best validation we have |
| Brand moat (240 brands, 17 of world's top 100 spirits) | 3 | "200-year-old company, irreplaceable inventory" — matches thesis ^8 |
| India / EM growth story | 3 | PR #1 in EM at 45% share, India +6% growth, 17M new adults/yr — exactly the durable-demand argument |
| Sector-wide compression, not PR-specific | 3 | Diageo +1.7%, Campari +1%, Remy -1%, all multiples down |
| EUR 70 floor zone | 3 | Hessel sees EUR 68 as realistic bottom — almost exactly our T2 alert level |
| Trading at trough multiples | 2, 3, 4 | Forward P/E 12–13x, vs historic 20x+ |
| Mean-reversion upside if you believe in business | 3 | +100% target = ~EUR 130, matches our TP2 (EUR 130) |
| Issue | Source | Implication |
|---|---|---|
| Dividend not covered by FCF — FY25 FCF EUR 1.1B vs dividend ~EUR 1.2B; EPS EUR 5.84 vs DPS EUR 4.78 (82% payout) | 2 | Thesis's "FCF < EUR 800M for 2 yrs → exit" trigger already brushing the line. Cut risk is real, not theoretical |
| EV-basis valuation much less attractive — EUR 10B net debt → EV ~EUR 30B → EV/profit 18–20x, EV/FCF ~28x | 2 | Our 13.5x P/E framing understates capital structure. Doesn't kill the thesis but sharpens the "no margin of safety on pessimistic earnings" risk |
| Analyst consensus 2029 EPS still below 2025 (EUR 6.66 vs 7.26) | 2 | Bear interpretation: the recovery to normalized EPS we model isn't priced in by analysts. Bull interpretation: analyst pessimism is exactly the setup for mean-reversion |
| GLP-1 weight-loss drugs — 12% of US adults use them (vs 3% in 2021), reduce alcohol consumption 36–68% | 3 | NEW structural overhang not in thesis. Affects ~10–15% volume bear case in US. Hessel is bullish AND flags this. Worth adding as a re-score trigger |
| Cannabis legalization — heavy users drink ~33% less alcohol; legalization in US, Germany, etc. | 3 | NEW structural overhang not in thesis. Hessel calls it the #1 substitute, not "healthy lifestyle." US-centric impact |
| Industry inventory glut — top-5 producers hold $22B inventory, higher than 2008–09 | 3 | Suggests US destocking duration may be longer than our "by FY27" exit trigger assumes |
| "No clear bottom in sight" — revenue/profit downward for several quarters, no inflection | 4 | Cautionary read, but PARTIALLY OUTDATED — Q3 FY26 (Apr 16) showed +0.1% organic and China improving to -7%. Steffen's video doesn't capture that |
| Brown-Forman merger rumor as "sign of weakness" | 4 | STALE — talks officially terminated Apr 28 (commit eb6521d). Per shr-036, no longer a tranche-suspension trigger. The mere fact that they were exploring the deal does suggest internal acknowledgment of pressure, but that's already in the price |
| Generic "brands are gone" — Kraft Heinz / Nike analogy | 1 | Lowest-signal critique. Doesn't engage with insider buying, aged inventory, or EM exposure. Discount appropriately |
T1 status (HOLD): None of the four videos surfaces a thesis-breaking issue. Hessel substantively validates the family-led / EM / brand-moat pillars. The two bears (2, 4) confirm the H1 weakness we already priced in.
T2 (EUR ~220, ~3 shares, deferred to FY26 results in Aug 2026 per commit eb6521d):
New items worth folding into the next red-flag check / re-score:
The four videos collectively don't change the thesis but tighten the bull case: the recovery requires China to keep improving (Q3 FY26 is the first positive signal, ratify in FY26 results), the dividend must hold, and GLP-1/cannabis volume drag must stay below the EM-growth offset. The Brown-Forman rumor in video 4 is stale (resolved Apr 28). Hessel (video 3) is essentially restating our thesis with more EM detail; that's reassuring confluence, not new information.